systemic light-chain AL amyloidosis
Haematology · 2021–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| daratumumab In combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD), for the treatment of newly diagnosed patients with systemic light-chain AL… | May 2022 | Not recommended | input received Myeloma Australia · Leukaemia Foundation · Australian Amyloidosis Network |
| daratumumab Newly diagnosed patients with systemic light-chain AL amyloidosis, administered in combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for… | Nov 2021 | Not recommended | 21 individuals Myeloma Australia · Leukaemia Foundation · Australian Amyloidosis Network |
Who spoke
Myeloma Australia · Leukaemia Foundation · Australian Amyloidosis Network
What the PBS pays
$225M in government benefit over 2024–25, across 31,520 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| daratumumab | $225M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.